Laura G.M. Heezen

Laura G.M. Heezen

Auto-generated profile, based on publicly available information

Laura G.M. Heezen

Department of Human Genetics Leiden University Medical Center Leiden the Netherlands

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
LHL.G.M. Heezen
L.G.M. Heezen
TATamim Abdelaal
Tamim Abdelaal
MPM. van Putten
M. van Putten
AAAnnemieke Aartsma-Rus
Annemieke Aartsma-Rus
AMAhmed Mahfouz
Ahmed Mahfouz
PSPietro Spitali
Pietro Spitali
Duchenne muscular dystrophy is caused by mutations in the DMD gene, leading to lack of dystrophin. Chronic muscle damage eventually leads to histological alterations in skeletal muscles. The identification of genes and cell types driving tissue remodeling is a key step to developing effective therapies. Here we use spatial transcriptomics in two Duchenne muscular dystrophy mouse models differing in disease severity to identify gene expression signatures underlying skeletal muscle pathology and to directly link gene expression to muscle histology. We perform deconvolution analysis to identify cell types contributing to histological alterations. We show increased expression of specific genes in areas of muscle regeneration (Myl4, Sparc, Hspg2), fibrosis (Vim, Fn1, Thbs4) and calcification (Bgn, Ctsk, Spp1). These findings are confirmed by smFISH. Finally, we use differentiation dynamic analysis in the D2-mdx muscle to identify muscle fibers in the present state that are predicted to become affected in the future state.

1 May 2023 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
DCDonnie Cameron
Donnie Cameron
TATooba Abbassi‐Daloii
Tooba Abbassi‐Daloii
LHLaura G.M. Heezen
Laura G.M. Heezen
NVNienke M. van de Velde
Nienke M. van de Velde
ZKZaïda Koeks
Zaïda Koeks
HKHermien Kan
Hermien Kan
Background: Becker muscular dystrophy (BMD) is an X‐linked disorder characterized by slow, progressive muscle damage and muscle weakness. Hallmarks include fibre‐size variation and replacement of skeletal muscle with fibrous and adipose tissues, after repeated cycles of regeneration. Muscle histology can detect these features, but the required biopsies are invasive, are difficult to repeat and capture only small muscle volumes. Diffusion‐tensor magnetic resonance imaging (DT‐MRI) is a potential non‐invasive alternative that can calculate muscle fibre diameters when applied with the novel random permeable barrier model (RPBM). In this study, we assessed muscle fibre diameters using DT‐MRI in BMD patients and healthy controls and compared these with histology.Methods: We included 13 BMD patients and 9 age‐matched controls, who underwent water‐fat MRI and DT‐MRI at multiple diffusion times, allowing RPBM parameter estimation in the lower leg muscles. Tibialis anterior muscle biopsies were taken from the contralateral leg in 6 BMD patients who underwent DT‐MRI and from an additional 32 BMD patients and 15 healthy controls. Laminin and Sirius‐red stainings were performed to evaluate muscle fibre morphology and fibrosis. Twelve ambulant patients from the MRI cohort underwent the North Star ambulatory assessment, and 6‐min walk, rise‐from‐floor and 10‐m run/walk functional tests.Results: RPBM fibre diameter was significantly larger in BMD patients (P = 0.015): mean (SD) = 68.0 (25.3) μm versus 59.4 (19.2) μm in controls. Inter‐muscle differences were also observed (P ≤ 0.002). Both inter‐ and intra‐individual RPBM fibre diameter variability were similar between groups. Laminin staining agreed with the RPBM, showing larger median fibre diameters in patients than in controls: 72.5 (7.9) versus 63.2 (6.9) μm, P = 0.006. However, despite showing similar inter‐individual variation, patients showed more intra‐individual fibre diameter variability than controls—mean variance (SD) = 34.2 (7.9) versus 21.4 (6.9) μm, P < 0.001—and larger fibrosis areas: median (interquartile range) = 21.7 (5.6)% versus 14.9 (3.4)%, P < 0.001. Despite good overall agreement of RPBM and laminin fibre diameters, they were not associated in patients who underwent DT‐MRI and muscle biopsy, perhaps due to lack of colocalization of DT‐MRI with biopsy samples.Conclusions: DT‐MRI RPBM metrics agree with histology and can quantify changes in muscle fibre size that are associated with regeneration without the need for biopsies. They therefore show promise as imaging biomarkers for muscular dystrophies.

1 May 2026 in The Journal of Pathology
Verified
Journal Article
Open access
PDF file
LHLaura Gm Heezen
Laura Gm Heezen
QMQirong Mao
Qirong Mao
SNStefan Nicolau
Stefan Nicolau
CRClaudio Novella Rausell
Claudio Novella Rausell
JWJulia van der Weerd
Julia van der Weerd
PSPietro Spitali
Pietro Spitali
Dystrophinopathies are caused by pathogenic variants in the DMD gene, resulting in partial (Becker) or complete loss (Duchenne) of dystrophin. Becker (BMD) and Duchenne muscular dystrophy (DMD) are characterized by progressive muscle wasting, fatty replacement, fibrosis, and loss of function. To study histopathological changes, we used Visium spatial transcriptomics to profile skeletal muscle biopsies of patients affected by dystrophinopathy ( n = 8) and healthy controls ( n = 4). We estimated the proportion of cell types and their spatial localization across samples applying a deconvolution strategy using previously published single‐nucleus RNA‐sequencing data. We identified genes enriched in fat patches and cell types such as fibroadipogenic progenitors (FAPs) in areas of active pathology. Using expression data of ligand–receptor pairs, we highlight cell–cell communications leading to fibrotic and adipogenic lesions. Finally, analysis of gene expression gradients in areas of adjacent muscle and fat, allowed the identification of genes associated with muscle areas committed to becoming fat. © 2026 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

18 March 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
LHL.G.M. Heezen
L.G.M. Heezen
TATamim Abdelaal
Tamim Abdelaal
MPMichel Van Putten
Michel Van Putten
AAAnnemieke Aartsma-Rus
Annemieke Aartsma-Rus
AMAhmed Mahfouz
Ahmed Mahfouz
PSPietro Spitali
Pietro Spitali
Duchenne muscular dystrophy (DMD) is caused by mutations in the DMD gene, leading to lack of dystrophin. Chronic muscle damage eventually leads to histological alterations in skeletal muscles. The identification of genes and cell types driving tissue remodeling is a key step to develop effective therapies. Here we use spatial transcriptomics in two DMD mouse models differing in disease severity to identify gene expression signatures underlying skeletal muscle pathologies and directly link this to the muscle histology. Deconvolution analysis allowed the identification of cell types contributing to histological alterations. We show how the expression of specific genes is enriched in areas of muscle regeneration ( Myl4 , Sparc , Hspg2 ), fibrosis ( Vim , Fn1 , Thbs4 ) and calcification ( Bgn , Ctsk , Spp1 ). Finally, our analysis of differentiation dynamics in the severely affected D2-mdx muscle shows a subset of the muscle fibers are predicted to become affected in its future state. Genes associated with tissue remodeling could enable to design new diagnostic and therapeutic strategies for DMD.

20 October 2025 in bioRxiv
Verified
Preprint
Open access
QMQirong Mao
Qirong Mao
AAAlireza Ahmadi
Alireza Ahmadi
SVSharon de Vries
Sharon de Vries
LHLaura G.M. Heezen
Laura G.M. Heezen
Ophélie VaccaOphélie Vacca
Ophélie Vacca
PSPietro Spitali
Pietro Spitali
Duchenne muscular dystrophy (DMD) is marked by progressive muscle degeneration due to dystrophin deficiency. Despite cognitive impairments in up to one–third of patients, central nervous system (CNS)–targeted dystrophin restoration remains relatively underexplored compared to muscle-focused therapies. Since dystrophin is expressed in the brain during development and postnatally, it is important to assess which aspects of CNS pathology could be rescued. However, studying Dmd is difficult due to its size, low–abundance transcripts, and with multiple isoforms, limiting the sensitivity and isoform resolution of standard sequencing methods. To overcome these limitations, we applied Xenium spatial transcriptomics to target splice junctions, enabling isoform-specific and exon 51 skipping events detection across brain regions and cell types. Using this approach, we analyzed mdx52 mice lacking the full–length and Dp140 isoforms, treated with two exon 51 skipping therapies (antisense oligonucleotides or AAV–U7ex51). We observed distinct spatial expression patterns in the wild type brain between the full-length isoforms (Dp427c/m/p1) and shorter isoforms (Dp71 and Dp40). The full-length isoforms were predominantly expressed in cortex layers 2/3–6b and the CA1 region, while the shorter isoforms were localized to cortex layer 1 and the dentate gyrus. Among the exon skipping therapies tested, U7ex51 delivered neonatally induced broad exon skipping in neurons and effectively restored full-length isoforms in the targeted cells. This study introduces the first subcellular-resolution spatial transcriptomic atlas of dystrophin presence and rescue in the CNS and demonstrates a framework for evaluating gene therapies in spatially and transcriptionally complex tissues such as the brain.

19 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
QMQirong Mao
Qirong Mao
LHLaura Gm Heezen
Laura Gm Heezen
SVSharon de Vries
Sharon de Vries
NVNynke Verwoerd
Nynke Verwoerd
AAAnnemieke Aartsma-Rus
Annemieke Aartsma-Rus
AMAhmed Mahfouz
Ahmed Mahfouz
Duchenne muscular dystrophy (DMD) is accompanied by cognitive and neurodevelopmental difficulties. To investigate how the loss of different dystrophin isoforms affects gene expression across brain regions, we performed spatial transcriptomics on brains from mdx and mdx 4cv mouse models (lacking Dp427 or Dp427+Dp140 respectively) and healthy controls aged 2 weeks. Both dystrophic models showed transcriptional changes converging on myelin and oligodendrocyte biology and oxidative phosphorylation, but with distinct regional patterns. In mdx mice, myelin genes were upregulated in the amygdala and hippocampus and downregulated in fiber tract regions, while mitochondrial genes were upregulated in most regions but downregulated in the thalamus and isocortex. In mdx 4cv mice, myelin genes were broadly upregulated and mitochondrial genes downregulated across almost all regions. Direct comparison between mdx and mdx 4cv mice demonstrated that the additional loss of Dp140 expanded localized myelin upregulation across the brain and shifts the mitochondrial response toward widespread downregulation. These differences in regional changes between the mouse models is in line with their dystrophin isoform(s) loss. Our findings provide a molecular basis for the brain-related impairments of DMD and a foundation for future therapeutic studies.